Goal
To in and inactivate HIV virus and other pathogens
Problem
HIV/AIDS infection and related viral diseases
Concept Summary
CSA-54 is a synthetically derived bile-acid molecule that mimics cationic antimicrobial peptides. Its positive charge electrostatically attracts it to the negatively charged viral envelope, disrupting the membrane and preventing infection of host cells.
Detailed Description
Ceragenins are amphiphilic molecules built on a cholanic acid scaffold with attached amino-acid side chains, giving them a net positive charge. CSA-54, the most highly charged member of the family, binds to viral and bacterial membranes, causing depolarization and loss of integrity. In vitro studies at Vanderbilt showed that CSA-54 can inactivate multiple HIV strains and also display activity against influenza, smallpox, and herpes viruses. The compound can be formulated as a topical cream, ointment, pill, or injection, pending further development and regulatory approval.
Principles
- Cationic selective antimicrobial action
- Electrostatic attraction to negatively charged membranes
- Membrane depolarization and disruption
Scientific Domains
Materials
- Bile-acid (cholic acid) derivative
- Amino-acid side chains
- Amphiphilic scaffold
Mechanisms of Action
- Binding to viral envelope lipids
- Disruption of membrane integrity
- Depolarization of bacterial cytoplasmic membranes
Applications
- HIV/AIDS therapy
- Broad-spectrum antiviral treatment
- Antibacterial agent
Claimed Performance
Broad-spectrum activity against all known HIV strains; also active against influenza, smallpox, and herpes viruses in vitro.
Experimental Evidence
Early test-tube (in vitro) studies at Vanderbilt reproduced antiviral activity many times; membrane depolarization demonstrated in bacterial assays; peer-reviewed publication pending.
Replication Status
Results reproduced multiple times in the Vanderbilt laboratory; no independent third-party replication reported.
Limitations
- Only in vitro data available
- No human clinical trials yet
- Regulatory approval pending
Red Flags
- Claims of a cure before peer-reviewed data
- Limited published data and lack of independent replication
